Getting emotional support
Some amount of feeling depressed, anxious, or worried is normal when liver cancer is a part of your life. Some people are affected more than others. But everyone can benefit from help and support from other people, whether friends and family, religious groups, support groups, professional counselors, or others. Learn more in Life After Cancer or Distress in People with Cancer.
Because there are only a few effective ways to prevent or treat liver cancer at this time, there is always a great deal of research going on in the area of liver cancer. Scientists are looking for causes and ways to prevent liver cancer, and doctors are working to improve treatments.
The most effective way to reduce the worldwide burden of liver cancer is to prevent it from happening in the first place. Some scientists believe that vaccinations and improved treatments for hepatitis could prevent about half of liver cancer cases worldwide. Researchers are studying ways to prevent or treat hepatitis infections before they cause liver cancers. Research into developing a vaccine to prevent hepatitis C is ongoing. Progress is also being made in treating chronic hepatitis.
Several new blood tests are being studied to see if they can detect liver cancer earlier than using AFP and ultrasound. One that is promising is called DKK1.
Newer techniques are being developed to make both partial hepatectomy and liver transplants safer and more effective.
Adding other treatments to surgery
An active area of research uses adjuvant therapies – treatments given right after surgery – to try to reduce the chances that the cancer will return. Most of the studies so far using chemotherapy or chemoembolization after surgery have not shown that they help people live longer. Research studies are also looking into newer drugs, like targeted therapy and may prove to be more effective. Some promising results have also been seen with radioembolization, but these need to be confirmed in larger studies. Another area of study has been the use of anti-viral therapy in people with liver cancer related to having viral hepatitis to see if it improves outcomes after surgery.
Doctors are also studying ways to make more liver cancers resectable by trying to shrink them before surgery. Studies are now looking at different types of neoadjuvant therapies (therapies given before surgery), including targeted therapy, chemotherapy, ablation, embolization, and radiation therapy. Early results have been promising but have only looked at small numbers of patients.
In laparoscopic surgery, several small incisions are made in the abdomen, and special long, thin surgical instruments are inserted to view and cut out the diseased portion of the liver. It does not require a large incision in the abdomen, which means there is less blood loss, less pain after surgery, and a quicker recovery.
At this time, laparoscopic surgery is still considered experimental for liver cancer. It is being studied mainly in patients with small tumors in certain parts of the liver that can be easily reached through the laparoscope.
Determining recurrence risk after surgery
After a partial hepatectomy, one of the biggest concerns is that the cancer might come back (recur). Knowing someone's risk for recurrence after surgery might give doctors a better idea of how best to follow up with them, and may someday help determine who needs additional treatment to lower this risk.
Various researchers are studying ways to predict if the cancer may come back by testing the liver cells in the surgery sample through genetic profiling. . These studies are promising but will need to be confirmed in other larger studies before it is widely used.
Only a small portion of patients with liver cancer are candidates for a liver transplant because of the strict criteria they need to meet (based mainly on the size and number of tumors). Some doctors are now looking to see if these criteria can be expanded, so that people who are otherwise healthy but have slightly larger tumors might also be eligible.
The main problem with using radiation therapy against liver cancer is that it also damages healthy liver tissue. Researchers are now working on ways to focus radiation therapy more narrowly on the cancer, sparing the nearby normal liver tissue. One approach being studied is called brachytherapy. In this treatment, catheters (thin tubes) are placed in the tumor and then pellets that give off radiation are put into the catheters for a short time. After the treatment, both the pellets and the catheters are removed. This allows radiation to be targeted to the cancer with less harm to the normal liver.
New drugs are being developed that work differently from standard chemotherapy drugs. These newer drugs target specific parts of cancer cells or their surrounding environments.
Tumor blood vessels are the target of several newer drugs. Liver tumors need new blood vessels to grow beyond a certain size. The drug sorafenib (Nexavar), which is already used for some liver cancers that can't be removed surgically, works in part by hindering new blood vessel growth. This drug is now being studied for use earlier in the course of the disease, such as after surgery or trans-arterial chemoembolization (TACE). Researchers are also studying whether combining it with chemotherapy may make it more effective.
Regorafenib (Stivarga®) is another targeted drug that is showing promise in treating liver cancers It is being studied in patients who have not responded to sorafenib. Cabozantinib is another small molecule inhibitor that has been shown to reduce tumor growth and stop new blood vessel growth
New forms of chemotherapy combined with other treatments are being tested in clinical trials. A small number of tumors respond to chemotherapy, although it has not yet been shown to prolong survival.
Chemotherapy drugs, such as oxaliplatin, capecitabine, gemcitabine, and docetaxel, are being tested against liver cancer in clinical trials. Oxaliplatin has shown promising results in early studies when given in combination with doxorubicin and also when given with gemcitabine and the targeted therapy drug cetuximab (Erbitux®).
A newer approach to treatment is the use of a virus, known as JX-594. This started as the same virus that was used to make the smallpox vaccine, but it has been altered in the lab so that it mainly infects cancer cells and not normal cells. A solution containing the virus is injected into liver cancers, and the virus can enter the cancer cells, where it causes them to die or to make proteins that result in them being attacked by the body’s immune system. Early results of this treatment against advanced liver cancer have been promising, even in patients who have already had other treatments.
More information from your American Cancer Society
We have a lot more information that you might find helpful. Explore www.cancer.org or call our National Cancer Information Center toll-free number, 1-800-227-2345. We’re here to help you any time, day or night.
Other organizations and websites*
In addition to the American Cancer Society, other sources of patient information and support include:
American Liver Foundation
Toll-free number: 1-800-GO-LIVER (1-800-465-4837)
Provides free information on primary liver cancer, liver transplants, and other liver diseases. They offer support groups in some areas, and also have materials in Spanish and Chinese
National Cancer Institute
Toll-free number: 1-800-4-CANCER (1-800-422-6237)
Provides free information on all types of cancer, living with cancer, support information for families of people with cancer, research, and more
National Coalition for Cancer Survivorship
Toll-free number: 1-888-650-9127
1-877-NCCS-YES (622-7937) for some publications and Cancer Survivor Toolbox® orders
Offers information on work, health insurance, and more. The Cancer Survival Toolbox is a free, self-learning audio program to help cancer survivors and caregivers develop practical tools needed to deal with the diagnosis, treatment and challenges of cancer. Listen online or order CDs. Also in Spanish and Chinese
Patient Advocate Foundation
Toll-free number: 1-800-532-5274
Helps mediate among the patient and insurer, employer, or creditors to resolve insurance, job, or debt problems related to their cancer. Helps people get access to care and keep job and financial stability
United Network for Organ Sharing
Toll-free number: 1-888-894-6361
Maintains international waiting lists and medical databases to help match organ donors and recipients. Offers a free publication, “The Patient Information Kit about Transplantation” (visit the UNOS Store online) and a special website on transplants at www.transplantliving.org
American Cancer Society. Cancer Facts & Figures 2016. Atlanta, Ga: American Cancer Society; 2016.
American Joint Committee on Cancer. Liver. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010:191–195.
Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: Results of a multicenter phase 2 study. Cancer. 2008;112:2733–2739.
Fong,Y, Dupey,DE,, Feng M, Abou-Alfa G. Cancer of the liver. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2015:696-714.
Brandi G, de Rosa F, Agostini V, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist. 2013;18(12):1256-7. Epub 2013 Nov 13.
Bruix J, Tak WY, Gasbarrini A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013 Nov;49(16):3412-9. Epub 2013 Jun 25.
Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1230.
El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-1127.
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255.
Graf H, Jüngst C, Straub G, et al. Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion. 2008;78:34–38.
Hassan MM, Spitz MR, Thomas MB, et al. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Case-control study. Int J Cancer. 2008;123:1883–1891.
Heo J, Reid T, Ruo L, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013 Mar;19(3):329-336. Epub 2013 Feb 10.
Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995–2004.
Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012. Accessed April 23, 2012.
Ishizuka M, Kubota K, Shimoda M, Kita J, Kato M, Park KH, Shiraki T. Effect of menatetrenone, a vitamin k2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial. Anticancer Res. 2012 Dec;32(12):5415-5420.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Canc J Clin. 2011;61:69–90.
Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: How can outcomes be improved? Oncologist. 2010;15(suppl 4):42–52.
Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:43–58.
Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: Rationale and overview. Radiology. 2011;259:641–657.
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
Maheshwari S, Sarraj A, Kramer J, El-Serag HB. Oral contraception and the risk of hepatocellular carcinoma. J Hepatol. 2007;47:506–513.
Marrero JA, Fontana RJ, Fu S, et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol. 2005;42:218–224.
Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: The effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol. 2009;44:470–475.
National Cancer Institute. Physician Data Query (PDQ). Adult Primary Liver Cancer Treatment. . Accessed at www.cancer.gov/cancertopics/pdq/treatment/adult-primary-liver/healthprofessional on February 29, 2016 .
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. V.1..2016. Accessed at www.nccn.org on February 29, 2016.
Onaca N, Davis GL, Jennings LW, Goldstein RM, Klintmalm GB. Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl. 2009 Jun;15(6):574-80.
Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2012 Annual Data Report: liver. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2012. Accessed at http://srtr.transplant.hrsa.gov/annual_reports/2012/pdf/03_liver_13.pdf on November 11, 2014
Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD001199.
Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013 Jan;14(1):55-63. Epub 2012 Nov 20.
Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012 Aug;13(8):817-826. Epub 2012 Jun 26.
Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992–2998.
Surveillance, Epidemiology and End Results (SEER) SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.
Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27:843–850.
Toh HC, Chen PJ, Carr BI, et al. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer. 2013 Jan 15;119(2):380-387. Epub 2012 Jul 25.
Uhm JE, Park JO, Lee J, et al. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009;63:929–935.
United States Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress. A Report of the Surgeon General. Accessed at www.surgeongeneral.gov/library/reports/50-years-of-progress/full-report.pdf on January 22, 2014.
Weber S, Jarnagin W, Duffy A, et al. Liver and bile duct cancer. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:1569–1579.
Ye SL, Takayama T, Geschwind J, et al. Current approaches to the treatment of early hepatocellular carcinoma. Oncologist. 2010;15(suppl 4):34–41.
Yeo W, Chung HC, Chan SL, et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol. 2012 Sep 20;30(27):3361-3367. Epub 2012 Aug 20.
Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013 Oct 10;31(29):3647−3655. Epub 2013 Sep 3.
Zhang CH, Xu GL, Jia WD, Ge YS. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: A meta-analysis of randomized controlled trials. Int J Cancer. 2009;124:2982–2988.
Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage IIIA hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135:1437–1445.
Last Medical Review: 03/31/2016
Last Revised: 04/28/2016